Common use of RESULTS AND PUBLICATIONS Clause in Contracts

RESULTS AND PUBLICATIONS. All data and results obtained within the CLINICAL TRIAL as well as any derivative works and intelectual/industrial property rights arising therefrom are the property of the SPONSOR, and the Parties are bound to the provisions of the laws governing these issues. This does not preclude the right of the PRINCIPAL INVESTIGATOR and of the FOUNDATION to use the results in their respective professional activities subject to the SPONSOR’s intellectual/industrial property rights and to the terms of the PROTOCOL. Under the provisions of RD 1090/2015, upon completion of the CLINICAL TRIAL, the SPONSOR shall publish the results, whether positive of negative, in scientific media accessible to the public. If the SPONSOR has not published the CLINICAL TRIAL final results, the PRINCIPAL INVESTIGATOR can disseminate any data, discoveries or inventions through journals or scientific publications, making reference at least to the SPONSOR. This shall be conducted according to following criteria: Trials on non-marketed products: during the first year, once authorized and marketed in any country; Trials conducted after product has been marketed, during the following year after the completion of the Trial, except when there is a commitment to publish the results in a medical journal submitted to peer review, or if there is an infringement to national law. The SPONSOR shall receive for his/her review, a copy of the text proposed for publication and/or dissemination at least forty-five (45) days before it is submitted to a scientific journal and at least twenty (20) days before it is summarized as an abstract. In any case, the PRINCIPAL INVESTIGATOR may only use these data subject to express prior written authorization from the SPONSOR.

RESULTS AND PUBLICATIONS. All TRIAL data and results obtained within the CLINICAL TRIAL results, as well as any derivative works resulting studies and intelectual/industrial property rights arising therefrom patent rights, are the property of the SPONSOR, and the Parties are bound to the provisions of the laws governing these issuescomply with relevant legislation. This does not preclude the right of the PRINCIPAL INVESTIGATOR and of the FOUNDATION to use from using the results in their respective professional activities subject to the SPONSOR’s intellectual/industrial property rights and to the terms of the PROTOCOLactivities. Under the As per provisions of RD 1090/2015223/2004, upon completion of once the CLINICAL TRIALTRIAL is finished, the SPONSOR shall is bound to publish the results, whether positive of negative, in scientific media accessible to the public. If the SPONSOR has not published the CLINICAL TRIAL final results, the PRINCIPAL INVESTIGATOR can disseminate any the data, discoveries or inventions through journals or scientific publications, making reference at least to the SPONSOR, at least. This shall be conducted according to following criteria: Trials on non-marketed products: during the first year, once authorized and marketed in any country; Trials conducted after product has been marketed, during the following year after the completion of the Trial, except when there is a commitment to publish the results in a medical journal submitted to peer review, or if there is an infringement to national law. The SPONSOR shall receive for his/her review, a copy of the text proposed for publication and/or dissemination dissemination, at least forty-five (45) days before it is submitted sent to a scientific journal and at least twenty (20) days before it is summarized as an abstract. In any case, the PRINCIPAL INVESTIGATOR may can only use these this data subject to express prior written authorization on purpose from the SPONSORSPONSOR is issued.

RESULTS AND PUBLICATIONS. All data and results obtained within the CLINICAL TRIAL as well as any derivative works and intelectualintellectual/industrial property rights arising therefrom are the property of the SPONSOR, and the Parties are bound to the provisions of the laws governing these issues. This does not preclude the right of the PRINCIPAL INVESTIGATOR and of the FOUNDATION to use the results in their respective professional activities subject to the SPONSOR’s intellectual/industrial property rights and to the terms of the PROTOCOL. Under the provisions of RD 1090/2015, upon completion of the CLINICAL TRIAL, the SPONSOR shall publish the results, whether positive of negative, in scientific media accessible to the public. If the SPONSOR has not published the final results of the CLINICAL TRIAL final resultsTRIAL, the PRINCIPAL INVESTIGATOR can disseminate any data, discoveries or inventions through journals or scientific publications, making reference at least to the SPONSOR. This shall be conducted according to the following criteria: Trials on non-marketed products: during the first year, once authorized year after authorization and marketed in any country; Trials conducted after the product has been marketed, during the following year after the completion of the Trial, except when there is a commitment to publish the results in a medical journal submitted to peer review, or if there is an infringement to national law. The SPONSOR shall receive for his/her review, a copy of the text proposed for publication and/or dissemination at least forty-five (45) days before it is submitted to a scientific journal and at least twenty (20) days before it is summarized as an abstract. In any case, the PRINCIPAL INVESTIGATOR may only use these this data subject to express prior written authorization from the SPONSOR.

RESULTS AND PUBLICATIONS. All data and results obtained within the CLINICAL TRIAL as well as any derivative works and intelectualintellectual/industrial property rights arising therefrom are the property of the SPONSOR, and the Parties are bound to the provisions of the laws governing these issues. This does not preclude the right of the PRINCIPAL INVESTIGATOR and of the FOUNDATION to use the results in their respective professional activities subject to the SPONSOR’s intellectual/industrial property rights and to the terms of the PROTOCOL. Under the provisions of RD 1090/2015, upon completion of the CLINICAL TRIAL, the SPONSOR shall publish the results, whether positive of negative, in scientific media accessible to the public. If the SPONSOR has not published the CLINICAL TRIAL final results, the PRINCIPAL INVESTIGATOR PRINCIPALINVESTIGATOR can disseminate any data, discoveries discoveries, or inventions through journals or scientific publications, making reference at least to the SPONSOR. This shall be conducted according to following criteria: Trials on non-marketed products: during the first year, once authorized authorised and marketed in any country; Trials conducted after product has been marketed, during the following year after the completion of the Trial, except when there is a commitment to publish the results in a medical journal submitted to peer review, or if there is an infringement to national law. The SPONSOR shall receive for his/her review, a copy of the text proposed for publication and/or dissemination at least forty-five (45) days before it is submitted to a scientific journal and at least twenty (20) days before it is summarized summarised as an abstract. In any case, the PRINCIPAL INVESTIGATOR may only use these data subject to express prior written authorization authorisation from the SPONSOR.

RESULTS AND PUBLICATIONS. All data and results obtained within the CLINICAL TRIAL as well as any derivative works and intelectualintellectual/industrial property rights arising therefrom are the property of the SPONSOR, and the Parties are bound to the provisions of the laws governing these issues. This does not preclude the right of the PRINCIPAL INVESTIGATOR and of the FOUNDATION to use the results in their respective professional activities subject to the SPONSOR’s intellectual/industrial property rights and to the terms of the PROTOCOL. Under the provisions of RD 1090/2015, upon completion of the CLINICAL TRIAL, the SPONSOR shall publish the results, whether positive of negative, in scientific media accessible to the public. If the SPONSOR has not published the CLINICAL TRIAL final results, the PRINCIPAL INVESTIGATOR PRINCIPALINVESTIGATOR can disseminate any data, discoveries discoveries, or inventions through journals or scientific publications, making reference at least to the SPONSOR. This shall be conducted according to following criteria: Trials on non-marketed products: during the first year, once authorized authorised and marketed in any country; Trials conducted after product has been marketed, : during the following year after the completion of the Trial, except when there is a commitment to publish the results in a medical journal submitted to peer review, or if there is an infringement to national law. The SPONSOR shall receive for his/her review, a copy of the text proposed for publication and/or dissemination at least forty-five (45) days before it is submitted to a scientific journal and at least twenty (20) days before it is summarized summarised as an abstract. In any case, the PRINCIPAL INVESTIGATOR may only use these data subject to express prior written authorization from the SPONSOR.